Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. ANI Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 5.6.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. ANI Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 5.6. Source depth averages 4 original sources per story, versus 4.7 across the same-window beat baseline. Fulgent Genetics appears in 1 tracked Healthcare story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Fulgent Genetics. Shared-story counts are live from our verified record — not editorial picks.
ANI Pharmaceuticals and Amneal Pharmaceuticals are preparing to report Q4 2025 results, with ANI expected to show significant double-digit growth in both revenue and earnings. These reports will provide a critical pulse check on the specialty generics market and the impact of recent portfolio expansions.
Source: Seeking Alpha · Seeking Alpha
Fulgent Genetics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
